Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trialResearch in context

• Κύριοι συγγραφείς: Masaaki Mori (Συγγραφέας), Kanako Yoshizaki (Συγγραφέας), Shinichi Watabe (Συγγραφέας), Mika Ishige (Συγγραφέας), Akinari Hinoki (Συγγραφέας), Takuya Kondo (Συγγραφέας), Tomoaki Taguchi (Συγγραφέας), Hisaya Hasegawa (Συγγραφέας), Tomoko Hatata (Συγγραφέας), Naoyuki Tanuma (Συγγραφέας), Kosuke Kirino (Συγγραφέας), Akihiro Hirakawa (Συγγραφέας), Takuya Naruto (Συγγραφέας), Minoru Imai (Συγγραφέας), Ryuji Koike (Συγγραφέας), Kenichiro Hosoi (Συγγραφέας), Satoshi Kusuda (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Elsevier, 2023-10-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Summary: Background: Pediatric patients with certain rare diseases are at increased risk of severe respiratory syncytial virus (RSV) infection. However, the prophylactic use of anti-RSV antibody (palivizumab) in these patients is not indicated at present in Japan. Methods: This first-in-the-world mu...